MAR 1 3 2002

Patent

Attorney's Dock :: No. 033072-026

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Robert H. Oakley, et al.

Application No.: 09/993,844

Filed: November 5, 2001

For: Modified G-Protein Coupled Receptors

Comparison of the protein of the p

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- [X] No additional fee for submission of an IDS is required.
- [] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- [] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (919) 941-9240

Date: 17 ach 12 2002

Melissa M. Hayworth
Registration No. 45,774



Patent Attorney's Docket No. <u>033072-026</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)				
Robert H. Oakley, et al.)	Group Art Unit: 3739	TOTAL	~	
Application No.: 09/993,844)	Examiner: Unassigned		AR 1)
Filed: November 5, 2001)		CENTER	× 20	*
For: Modified G-Protein Coupled Receptors)		IA 80700	002	Ü

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, the documents submitted herewith were cited in the application and are being provided for the Examiner's convenience.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404

Alexandria, VA 22313-1404

Phone: (919) 941-9240

By: M. Hayworth
Registration No. 45,774

Date: 12 2002

Substitute for form 1449A/PTO

Signature

INFORMATION DISCESSURE STATEMENT BY APPLICANT

MAR 1 3 2002

ATTORNEY'S DKT NO.	APPLICATI	ON N	Ō.	
033072-026	09/993,8	344		
APPLICANT		$\ddot{\mathbb{C}}$		
Robert H. Oakley, et al.		7		
FILING DATE	GROUP		Ā	5
November 5, 2001	1645	1.	スフ	

						C E	×	, 	
			U.S. PATENT DOO	UMENTS		<u>m</u>	002	- [
	U.S. Patent D	ocument				R37((
Examiner Initials	Number			tee or Applican Document	t	Date of Pabli (MM-DD-Y)			
-	6,110,693		Barak, et al.	Barak, et al.			08-29-2000		
	6,066,476		Tsien, et al.			05-23-20	000		
	5,891,646		Barak, et al.			04-06-19	999		
	5,777,079		Tsien, et al.			07-07-19	998		
	5,625,048		Tsien, et al.			04-29-19	997		
	4,981,784		Evans, et al.			01-01-19	991		
	4,816,567		Cabilly, et al.			03-28-19	989		
	4,493,890		Morris			01-15-19	985		
	4,491,632		Wands, et al.			01-01-19	985		
	4,472,500		Milstein, et al.			09-18-19	984		
	4,466,917		Nussenzweig, et a	l.		08-21-19	8-21-1984		
	4,451,570		Royston, et al.			05-29-19			
	4,444,887		Hoffmann			04-24-19	04-24-1984		
		F	OREIGN PATENT D	CUMENTS	•				
	Foreign Patent	Document							
Examiner Initials			Country	Country		te of Publication MM-DD-YYYY)	Trans	slatio	
	W088/03168	A1	PCT		05-05-		1 103	T	
	WO01/58923	A2	РСТ		08-16-	2001	1	T	
	WO98/44350	A1	PCT		10-08-	1998	1	T	
	WO00/12704	A2	PCT		03-09-	2000	1	T	
	WO99/66324	A2	PCT		12-23-	1999		T	
-	WO94/16684	A1	PCT		08-04-	1994		T	
	WO98/12310	A1	PCT		03-26-	1998		\top	
	•	NON F	ATENT LITERATUR	RE DOCUME	NTS				
Examiner Initials	item (book, ANGERS, S., et al.,	name of author magazine, jour	r (in CAPITAL LETTERS) rnal, serial, symposium, publisher, city and/or g-Adrenergic receptor din	title of the art catalog, etc.), c country where perization in livi	icle (wher date, page published. ing cells u	(s), volume-issue num sing bioluminescence	iber(s), resonan		
	3689, Proc.Natl. A	cad. Sci, USA.	is of the National Acade						
	Chemistry, Vol 257, Molecular Biology, I	No. 25, Septenc., USA.	ember 5, 1992, pp 1788	2-17890, The	American	Society for Biochemis	try and		
			olecular Biology of the C merican Society for Cell					_	
		abetes insipidu	rrestin-mediated desensi s, <u>Proceedings of the Na</u> Sci, USA.						
xaminer				Date					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Considered

A) T

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.	APPLICATION NO.
033072-026	09/993,844
APPLICANT	
Robert H. Oakley, et al.	
FILING DATE	GROUP
November 5, 2001	1645

						_	~ 11
			U.S. PATENT DOCUMENTS		<u> </u>	MAR	1 :
Examiner	U.S. Patent [Nocument Kind Code	Name of Patentee or Applican	t	Date of Éubli	ication	1.
Initials	Number	(if known)	of Cited Document		(MM-00-Y		<u> </u>
	4,427,783		Newman, et al.		01-27-19		
	4,399,121		Albarella, et al.		08-1 5 _1		<u> </u>
	4,342,566		Theofilopoulous, et al.		08-03519		
	4,341,761		Ganfield, et al.		07-27-19	982	
	4,016,043		Schuurs, et al.		04-05-19	977	
	3,850,752		Schuurs, et al.		11-26-19		
	3,654,090		Schuurs, et al.		04-04-19	972	
	RE31,006		Schuurs, et al.		08-03-19	982	
	4,816,397		Boss, et al.		03-28-19	989	
	6,150,393		Behan, et al.		11-21-20	000	
	6,107,324		Behan, et al.		08-22-20	000	
	6,140,509		Behan, et al.		10-31-20	000	
	5,989,835		Dunlay, et al.		11-23-19	999	
	•	F	DREIGN PATENT DOCUMENTS	•			
	Foreign Patent	Document					
Examiner Initials	No. and an	Kind Code	6	Date of Publication			nslatio
Illitiais	Number	(if known)	Country	111	MM-DD-YYYY)	Yes	+
							-
			PATENT LITERATURE DOCUME				
Examiner Initials			r (in CAPITAL LETTERS), title of the art rnal, serial, symposium, catalog, etc.), (_ publisher, city and/or country where	late, page			
	mediated β₂-Adrene	rgic Receptor S	erved Tyrosine Residue in G Protein-Co lequestration, <u>Journal of Biological Che</u> of for Biochemistry and Molecular Biolog	<u>nistry</u> , Vol	269, No. 4, January		
<u> </u>	BARAK, L.S., et al., Activation, Journal	, A β-Arrestin/G of Biological Ch	reen Fluorescent Protein Biosensor for a nemistry, Vol. 272, No. 44, October 31 cular Biology, Inc., USA.	Detecting	G Protein-coupled Red		can
	BARAK, L.S., et al.,	. The Conserve	d Seven-Transmembrane Sequence NP(perties of the eta_2 -Adrenergic Receptor, \underline{t}				
			cking and Surface Mobility of a Function lecular Pharmacology, 51, 1997, pp. 1		t β₂-Adrenergic Recep	tor-Gre	en
xaminer Signature			Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.	APPLICATION NO.
033072-026	09/993,844
APPLICANT	
Robert H. Oakley, et al.	
FILING DATE	GROUP
N	1 1045

		. <u> </u>		<u></u> _			\triangleright	
· ·			U.S. PATENT DOC	JMENTS		· · · · · · · · · · · · · · · · · · ·	- D	
	U.S. Patent [Document				C : F i	7 :	; ;
Examiner Initials	Number	Kind Code (if known)	Name of Patente of Cited D			Date of Public (MM-DD-YY	Υ Υ	*
	5,958,713		Thastrup, et al.			09- 28 -19	99	1
	5,804,387		Cormack, et al.			09- 0£ -19	98	
	5,491,084		Chalfie, et al.			02-13-19	96	
	5,532,157		Fink			07-02-19	96	
	5,482,835		King, et al.			01-09-19	96	
	5,468,854		McCabe, et al.			11-21-19	95	
	5,366,889		MacDonald, et al.			11-22-19	94	
	5,284,746		Sledziewski, et al.			02-08-19	94	
	5,576,436		McCabe, et al.			11-19-19	96	
			OREIGN PATENT DO	CUMENTS				
	Foreign Patent	1						
Examiner Initials	Number	Kind Code (if known)			Date of I (MM-D		Tran Yes	slatio n
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
	<u> </u>							
								1
						-		
	_	NON F	ATENT LITERATUR	E DOCUMEN	NTS			
Examiner Initials			r (in CAPITAL LETTERS), rnal, serial, symposium, c publisher, city and/or co	atalog, etc.), d	ate, page	e(s), volume-issue num		
	arrestin 2 during Hol No. 11, March 12,	<i>nologous Desei</i> 1999, pp. 756!	palization of the Cellular Ri Insitization of the Substance 5-7569, The American So	ce P Receptor, ciety for Bioch	Journal e emistry a	of Biological Chemistry and Molecular Biology,	, Vol. : Inc., U	274, SA.
	International Union	of Biochemistry	Improving and Using Gree and Molecular Biology, 4	48-455,1995,	Elsevier	Trends Journals, Oxfo	rd, UK	
	Association for the	Advancement of	torical Perspective, <u>Science</u> of Science, Washington, I	o.c.				ricar
			in-coupled receptor regula ol., Vol. 74, 1996, pp. 10				es and	
			lar Mechanisms of G Prot I 62, pp.1561-1565, 199				ensitiza	tion,
		stry, Vol 270, N	<i>Phosphorylation in Agoni</i> No. 42, October 20, 1995					
xaminer Signature				Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

MAR 1 3 2002

Substitute for form 1449A/PTO

INFORMATION DISCLOSUME STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.	APPLICA	TION	۷ο.	
033072-026	09/993	844		-
APPLICANT			Z	
Robert H. Oakley, et al.		í.	P .	1 1
FILING DATE	GROUP	7	20	()
November 5, 2001	1645	()		1.

						2.1			
			U.S. PATENT DOC	UMENTS					
	U.S. Patent	Document				2			
Examiner		Kind Code	Name of Patent	• •		Date of Public			
Initials	Number	(if known)	of Cited D	ocument	(MM-DD-YY	YY)			
						<u> </u>			
		FO	REIGN PATENT DO	CUMENTS					
	Foreign Paten	t Document		l					
Examiner Initials	Number	Kind Code (if known)	Country			ate of Publication (MM-DD-YYYY)	Translation Yes no		
mittais	NON PATENT LITERATURE DOCUMENTS								
	Inglude		(in CAPITAL LETTERS),			n appropriate) title of t	<u> </u>		
Examiner			nal, serial, symposium, c						
Initials			publisher, city and/or c						
	FERGUSON, S.S.G Science, Vol. 271,		B-arrestin in Mediating A 96, pp363-366.	gonist-Promoted	d G Prot	ein-Coupled Receptor In	nternalization,		
			enuating Cellular Respon						
		_	he Journal of Investigati of Investigative Dermat		/ Sympo	sium Proceedings, Vol 2	21, No. 1, pp		
			on Methods, pp.12-18, 1		niversity	Press, New York, U.S.			
			ion of the β ₂ -Adrenergic				yl Cyclase		
			nist Binding, Journal of for Biochemistry and Mo				25 , 1990, pp		
			lation of the Dopamine L				ntor Kinases		
	and β-arrestins, <u>Jo</u> u	urnal of Biologica	<u>I Chemistry</u> , Vol 276 No ular Biology, Inc., USA.						
	Adrenergic Recepto	or into Clathrin-co	tion of β-Arrestin with the pated Pits, Journal of Bio	logical Chemist	try, Vol.	275, No. 30, July 28, 2			
			ety for Biochemistry and nergic Receptor/Barrestin				rina		
			tional Academy of Scien						
	Proc.Natl. Acad. Sc								
	1550, June 22, 19	90.	tein That Regulates β-Ac						
	Endogenous Agonis	sts, Endomorphin	ion and Internalization of -1 and Endomorphin-2, <u>l</u>						
	Elsevier Science Lt								
	Proteins: Implicatio	ns for Receptor F	and Subcellular Localiza	to Gastroentero	<u>logy</u> , Di	gestive Disease Week a			
· · · · · · · · · · · · · · · · · · ·			stroenerological Associa in-Coupled Receptors in				uropontido		
		_	tor Regulation, pp. G792				шорерше		
			nce P-induced Trafficking 1999, The American Soc						
			Protein-Coupled Recept ochemistry, Vol. 35, No.		-		•		
	Adrenergic Recepto	or Kinase and B-A	ulation of β₂-Adrenergic trestin Determine Kineti nerican Society for Pharm	cs of Internaliza	ition, Mo	olecular Pharmacology,	ent of β ₂ - Vol. 51, No.		
Examiner Signature				Date Considered					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.	APPLICATION NO.					
033072-026	09/993,844					
APPLICANT						
Robert H. Oakley, et al.	ni O					
FILING DATE	GROUP .					
Nevember E 2001	1645 5					

				ALENTO.				0	
		<u> </u>	J.S. PATENT DOCU	WIENIS			<u> </u>	2	
Examiner Initials	U.S. Patent D	Kind Code (if known)		Name of Patentee or Applicant of Cited Document			Date of Publication (MM-DD-YYYY)		
		FOI	REIGN PATENT DO	CUMENTS					
	Foreign Patent	Document							
Examiner		Kind Code	C			ate of Publication (MM-DD-YYYY)	Trans	lation no	
Initials	Number	(if known)	Country			(IVIIVI-DD-TTTT)	Yes	no	
							 		
							-	<u> </u>	
	<u> </u>	<u> </u>						L	
		NON PA	TENT LITERATURE	DOCUMENT	ΓS				
Examiner Initials	Include item (book	, magazine, journ	in CAPITAL LETTERS), ti al, serial, symposium, ca publisher, city and/or co	talog, etc.), date	e, page	e(s), volume-issue num	the ber(s),		
	MHAOUTY-KODJA, S., et al., Constitutively Active Alpha-1b Adrenergic Receptor Mutants Display Different Phosphorylation and Internalization Features, Molecular Pharmacology, Vol. 55, No. 2, February 1999, pp. 339-347, The American Society for Pharmacology and Experimental Therapeutics.								
	ORMÖ, M., et al., <i>Crystal Structure of the Aequorea victoria Green Fluorescent Proteins</i> , Science Vol. 273, pp. 1392-1395, 1996, American Association for the Advancement of Science, Washington, D.C.								
	Dictates the Profile	of Receptor Rese	β-Arrestin with G Protein ensitization, Journal of Bi aciety for Biochemistry an	ological Chemis	try, Vo	ol 274, No. 45, Novem	d Endocy ber 5, 1	/ <i>tosis</i> 999,	
	Receptors Delineate	Two Major Clas	finities of Visual Arrestin ses of Receptors, <u>Journa</u> sciety for Biochemistry an	l of Biological C	hemis	try, Vol 275, No. 22, J	coupled une 2, 2	2000,	
	OAKLEY, R.H., et a	il., Molecular Dete in Complexes afte	erminatnts Underlying the er Receptor Endocytosis,	e Formation of S Journal of Biolo	Stable ogical (Intracellular G Protein- Chemistry, Vol 276, No	coupled 1. 22, Ju	ine 1,	
	2001, pp. 19452 - 19460, The American Society for Biochemistry and Molecular Biology, Inc., USA. YOKOE, Spatial Dynamics of GFP-tagged proteins investigated by local fluorescence enhancement, Nature Biotechnology, Vol. 14, pp. 1252 - 1256, October 14, 1996.								
	ZHANG, J., et al., <i>Cellular Trafficking of G Protein-coupled Receptor/</i> β-Arrestin Endocytic Complexes, <u>Journal of Biological Chemistry</u> , Vol 274, No. 16, April 16, 1999, pp. 10999-11006, The American Society for Biochemistry and Molecular Biology, Inc., USA.								
	ZHANG, J., et al., A Central Role for B-Arrestins and Clathrin-coated Vesicle-mediated Endocytosis in β_2 -Adrenergic Receptor Resensitization, Journal of Biological Chemistry, Vol. 272, No. 43, October 24, 1997, pp. 27005-27014, The American Society for Biochemistry and Molecular Biology, Inc., USA.								
Examiner Signature			_	Date Considered					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.